Mereo Biopharma Group PLC
NASDAQ:MREO

Watchlist Manager
Mereo Biopharma Group PLC Logo
Mereo Biopharma Group PLC
NASDAQ:MREO
Watchlist
Price: 3.39 USD 1.19% Market Closed
Market Cap: 521.6m USD
Have any thoughts about
Mereo Biopharma Group PLC?
Write Note

Mereo Biopharma Group PLC
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mereo Biopharma Group PLC
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Mereo Biopharma Group PLC
NASDAQ:MREO
Current Portion of Long-Term Debt
ÂŁ512k
CAGR 3-Years
-5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Current Portion of Long-Term Debt
ÂŁ2.4m
CAGR 3-Years
39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Current Portion of Long-Term Debt
$182k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Current Portion of Long-Term Debt
ÂŁ18.9m
CAGR 3-Years
-6%
CAGR 5-Years
34%
CAGR 10-Years
3%
No Stocks Found

Mereo Biopharma Group PLC
Glance View

Market Cap
521.6m USD
Industry
Biotechnology

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm is focused on oncology and rare diseases. The firm is focused on development and commercialization of therapeutic pharmaceutical products. Its pipeline consists of a diversified portfolio of clinical-stage product candidates, Etigilimab (MPH-313) for patients with advanced or metastatic solid tumors; Alvelestat (MPH-966) for the treatment of severe Alpha-1 Antitrypsin Deficiency (AATD) and coronavirus disease; Setrusumab (BPS-804) for the treatment of Osteogenesis Imperfecta (OI); Navicixizumab (OMP-305B83) for the treatment of platinum-resistant ovarian cancer; Acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and Leflutrozole (BGS-649) for the treatment of male infertility associated with hypogonadotropic hypogonadism (HH).

MREO Intrinsic Value
2.23 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Mereo Biopharma Group PLC's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
512k GBP

Based on the financial report for Dec 31, 2023, Mereo Biopharma Group PLC's Current Portion of Long-Term Debt amounts to 512k GBP.

What is Mereo Biopharma Group PLC's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
-5%

Over the last year, the Current Portion of Long-Term Debt growth was -96%. The average annual Current Portion of Long-Term Debt growth rates for Mereo Biopharma Group PLC have been -5% over the past three years .

Back to Top